title: Pharmacokinetics of leflunomide in Chinese healthy volunteers.
abstract: OBJECTIVE
  To study the pharmacokinetics of leflunomide in Chinese healthy volunteers.
  
  
  METHODS
  A single (20, 40, and 60 mg) and 30-d -repeated (20 mg/d) oral doses of leflunomide were performed on 18 (12 males and 6 females) and 6 (4 males and 2 females) Chinese healthy volunteers respectively. A771726, the active metabolite of leflunomide, in serum was determined by high performance liquid chromatography (HPLC). Data were analyzed by a 3p97 program on a Legend computer.
  
  
  RESULTS
  Serum concentration curves of A 771726 in single and repeated oral administration of leflunomide conformed to one compartment model of the first order absorption. Leflunomide was absorbed rapidly with T1/2,ka of between 1.15 h and 2.23 h in single oral administration. The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively. In repeated oral administration, steady stat e concentration was achieved within 30 d. The mean trough concentration was between 32.0 mg/L and 39.7 mg/L. The Cmax, Tmax, AU C0- 24 were (41.5 +/- 2.4) mg/L, (307 +/- 75) h, and (22099 +/- 1234) mg . h . L-1, respectively.
  
  
  CONCLUSIONS
  The absorption of leflunomide was rapid, and it s elimination was slow after oral administration. The pharmacokinetic results showed that it exhibited first order kinetic characteristics.
authors.affiliation: Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230032, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.forename: Hong-Wei
authors.initials: HW
authors.lastname: Yao
authors.forename: Yong
authors.initials: Y
authors.lastname: Jin
authors.forename: Yun-Fang
authors.initials: YF
authors.lastname: Zhang
authors.forename: Chang-Yu
authors.initials: CY
authors.lastname: Li
authors.forename: Yuan-Hai
authors.initials: YH
authors.lastname: Li
authors.forename: Shu-Yun
authors.initials: SY
authors.lastname: Xu
mesh_terms: D000328:Adult; D000814:Aniline Compounds / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D003437:Crotonates; D005260:Female; D006801:Humans; D006885:Hydroxybutyrates / Q000493:pharmacokinetics*; D007166:Immunosuppressive Agents / Q000378:metabolism / Q000493:pharmacokinetics*; D007555:Isoxazoles / Q000378:metabolism / Q000493:pharmacokinetics*; D000077339:Leflunomide; D008297:Male; D009570:Nitriles; D011355:Prodrugs / Q000378:metabolism / Q000493:pharmacokinetics*; D011897:Random Allocation; D014052:Toluidines
chemical_list: D000814:Aniline Compounds; D003437:Crotonates; D006885:Hydroxybutyrates; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; D011355:Prodrugs; D014052:Toluidines; C527525:teriflunomide; D000077339:Leflunomide